CRIMSON: A multicentre, randomised, sham-controlled (andactive controlled in the USA), double-masked, 72-week trial tostudy the safety, tolerability, pharmacokinetics, and efficacy of3 dosing regimens of intravitreal BI 764524 in patients withmoderately severe to severe non-proliferative diabeticretinopathy
Laufzeit: 01.01.2025 - 31.12.2026
imported
Kurzfassung
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy
